Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
99.442,76
-1,22%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Argen X SE (ARGX) Argen X SE (ARGX) Notizie

Argen X SE

ARGX
643,00
8,00 (1,26%)
31 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: Euronext
Tipo: Azione Ordinaria
Valuta: EUR

Ultime notizie

Data Ora Fonte Titolo
13/1/202507:00GLOBEargenx Highlights 2025 Strategic Priorities
06/1/202507:00GLOBEargenx to Present at 43rd Annual J.P. Morgan Healthcare..
27/12/202407:00GLOBEargenx Announces Approval of VYVDURA (efgartigimod alfa and..
26/11/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
20/11/202407:00GLOBEargenx Advances Clinical Development of Efgartigimod SC in..
11/11/202413:30GLOBEargenx and Zai Lab Announce Approval of VYVGART Hytrulo for..
05/11/202407:00GLOBEargenx to Participate at Upcoming Investor Conferences
31/10/202407:00GLOBEargenx Reports Third Quarter 2024 Financial Results and..
24/10/202407:00GLOBEargenx to Report Third Quarter 2024 Financial Results and..
15/10/202407:00GLOBEargenx Highlights Data Showing Patient Impact Across..
19/9/202407:00GLOBEargenx Announces Publication in The Lancet Neurology of..
28/8/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
25/7/202407:00GLOBEargenx Reports Half Year 2024 Financial Results and Provides..
18/7/202407:00GLOBEargenx to Report Half Year 2024 Financial Results and Second..
16/7/202406:30GLOBEargenx and Zai Lab Announce Approval of Efgartigimod Alfa..
25/6/202422:30GLOBEargenx Highlights Breadth of Autoimmune Pipeline with New..
21/6/202422:50GLOBEargenx Announces FDA Approval of VYVGART Hytrulo for Chronic..
17/6/202407:00GLOBEargenx to unveil its ‘Vision 2030: Taking Breakthrough..
04/6/202407:00GLOBEargenx to Present at Goldman Sachs 45th Annual Global..
09/5/202407:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
07/5/202423:30GLOBEargenx announces results of Annual General Meeting of..
07/5/202407:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
02/5/202407:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16/4/202407:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/3/202407:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/3/202421:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/3/202407:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
07/3/202422:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/2/202407:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/2/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
22/2/202407:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/2/202407:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
Apertura: 642,20 Min: 638,40 Max: 647,40
Chiusura: 635,00

La tua Cronologia

EU
ARGX
Argen X
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci